Ryvu Therapeutics Reports First Quarter 2020 Financial Results
Ryvu Therapeutics signs a grant agreement for the development of targeted immuno-oncology therapy
NodThera, Ryvu spin-off company, secures £44.5million ($54.5million) Series B Financing
What we do
We challenge current treatment paradigms
At Ryvu, we develop therapeutics that address clinical limitations of current treatments in oncology.
Our pipeline includes candidates with differentiated properties from kinase, synthetic lethality, immuno-oncology and immunometabolism programs.
Ryvu Therapeutics (Selvita Oncology) was founded in 2007. Since 2014, the company has been listed on Warsaw Stock Exchange under the ticker RVU.
Ryvu Therapeutics is organized for highly efficient R&D driven by breakthrough science, aiming to realize full value potential for its shareholders, partners and employees.See More